Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software. Chemaxon develops leading software products for chemical structure drawing, property prediction, search, and analysis. Used by research scientists globally, Chemaxon software helps to digitize the design, make, test and analyze (DMTA) lifecycle to discover the best new chemical leads. Certara and Chemaxon have had a long-term partnership spanning ten years, providing integrated solutions to the life sciences industry. The acquisition strategically positions Certara in the drug discovery biosimulation market at scale.
Read the full article: Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio //
Source: https://www.globenewswire.com/news-release/2024/07/09/2910780/0/en/Certara-to-Acquire-Chemaxon-to-Strengthen-Drug-Discovery-Software-Portfolio.html